)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genetic Signatures
Genetic Signatures (GSS) investor relations material
Genetic Signatures Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary7 Oct, 2026
Executive summary
Q1 FY2027 delivered lower operating costs and cash outflow following the Q4 FY2026 restructure; quarter-end cash and term deposits were $20.9m, with no debt.
Progress included commercial testing at Hvidovre Hospital, APAC market development and agreement on principal terms for a proposed all-scrip merger with Microba.
Financial highlights
Q1 sales were $4.0m versus $5.4m in Q1 FY2026; customer receipts were $4.2m.
Net operating cash outflow was $1.0m, versus $3.4m in Q4 FY2026 ($2.6m excluding $0.8m one-off redundancy payments) and $2.1m in Q1 FY2026.
Operating expenses, excluding cost of materials, were $4.0m, down 30% from $5.7m in Q1 FY2026; staff costs were $2.5m versus $3.8m YoY.
Quarter-end cash and term deposits were $20.9m, comprising $7.9m in bank balances and $13.0m in term deposits; cash and cash equivalents were $20.931m.
Outlook and guidance
Annualised operational cost savings of up to $5m remain the target following the restructure.
Cash outflows are expected to vary in coming months due to one-off product development costs and seasonal revenue changes.
Priorities include growing EasyScreen sales, broadening the testing menu, building on Hvidovre momentum and pursuing APAC opportunities, with disciplined capital deployment and improved unit economics.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genetic Signatures
- Merger forms a scaled diagnostics group with $30m revenue, global reach, and cost synergies.GSS
Trading update - Net loss reduced 30% to $14.0m as cost savings and new contracts offset a 7% revenue decline.GSSH2 2026
- Cost reductions and new contracts drive growth in EMEA and APAC, with U.S. plans on hold.GSSInvestor update
- Q3 FY2026 sales hit $3M, cash at $25.7M, and a major Danish supply deal was secured.GSSQ3 2026 TU
- Revenue down 42%, net loss up 27%, but FDA clearance opens US growth path.GSSH2 2024
- Revenue $8.7m, net loss $6.4m, margin down; US/EMEA growth and new leadership drive expansion.GSSH1 2026
- FY25 revenue up 66% to $14.4m, with record Q1 FY26 sales and all AGM resolutions approved.GSSAGM 2025 Presentation
- Revenue up 63% to $15.9m, gross margin 55%, US entry, and $30.9m cash reserves.GSSH2 2025
- Sales up 136% to $8.5M, gross margin 59%, $15.2M loss after $6.8M impairment, US entry begun.GSSH1 2025
Next Genetic Signatures earnings date
H1 202724 Feb, 2027
Genetic Signatures
Next Genetic Signatures earnings date
H1 202724 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Genetic Signatures Limited is a biotechnology company specializing in the development of molecular diagnostic solutions. The company focuses on creating innovative tests for the rapid detection of infectious diseases, leveraging its proprietary 3Base technology to improve accuracy and reduce diagnostic times. Genetic Signatures’ products are designed for use in clinical laboratories and hospitals, providing solutions for identifying pathogens responsible for conditions such as respiratory, gastrointestinal, and central nervous system infections. Genetic Signatures Limited is headquartered in Sydney, Australia, and its shares are listed on the ASX.